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ABSTRACT: The signaling pathways that regulate myelination in the peripheral nervous 34	
system (PNS) remain poorly understood. Phosphatidylinositol-4,5-bisphosphate 3-kinase 1A 35	
(PI3K), activated in Schwann cells by neuregulin and the extracellular matrix, has an essential 36	
role in the early events of myelination. Akt/PKB, a key effector of PI3K, was previously 37	
implicated in CNS, but not PNS myelination. Here we demonstrate that Akt plays a crucial role 38	
in axon ensheathment and in the regulation of myelin sheath thickness in the PNS. 39	
Pharmacological inhibition of Akt in DRG neuron-Schwann cell cocultures dramatically 40	
decreased MBP and P0 levels and myelin sheath formation without affecting expression of 41	
Krox20/Egr2, a key transcriptional regulator of myelination. Conversely, expression of an 42	
activated form of Akt in purified Schwann cells increased expression of myelin proteins, but not 43	
Krox20/Egr2, and the levels of activated Rac1. Transgenic mice expressing a membrane-44	
targeted, activated form of Akt under control of the 2’,3’-cyclic nucleotide 3’-phosphodiesterase 45	
(CNP) promoter, exhibited thicker PNS and CNS myelin sheaths, and PNS myelin 46	
abnormalities such as tomacula and myelin in/outfoldings centered around the paranodes and 47	
Schmidt Lanterman incisures. These effects were corrected by rapamycin treatment in vivo. 48	
Importantly, Akt activity in the transgenic mice did not induce myelination of non-myelinating 49	
	 3	
Schwann cells in the sympathetic trunk or Remak fibers of the dorsal roots although, in those 50	
structures, they wrapped membranes redundantly around axons. Together, our data indicate 51	
that Akt is crucial for PNS myelination driving axonal wrapping by unmyelinated and myelinated 52	
Schwann cells and enhancing myelin protein synthesis in myelinating Schwann cells. 53	
 54	
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SIGNIFICANCE STATEMENT: Although the role of the key serine/threonine kinase Akt in 57	
promoting CNS myelination has been demonstrated, its role in the PNS has not been 58	
established and remains uncertain. This work reveals that Akt controls several key steps of the 59	
PNS myelination. Firstly, its activity promotes membrane production and axonal wrapping 60	
independent of a transcriptional effect. In myelinated axons, it also enhances myelin thickness 61	
through the mTOR pathway. Finally, sustained Akt activation in Schwann cells leads to 62	
hyper/dysmyelination, mimicking some features present in neuropathies, such as Hereditary 63	
Neuropathy with Liability to Pressure Palsies or demyelinating forms of Charcot-Marie-Tooth 64	
disease. Together, these data demonstrate the role of Akt in regulatory mechanisms underlying 65	
axonal wrapping and myelination in the PNS.	66	67	
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INTRODUCTION 68	
Formation of the myelin sheath in the PNS is among the most dramatic examples of 69	
axon-glial interactions (Mirsky et al., 2008). Schwann cells are intimately associated with axons 70	
and adopt distinct fates as either myelinating or non-myelinating, i.e. Remak Schwann cells. 71	
These two Schwann cell phenotypes are distinguished by both their morphological relationship 72	
with the axon and by different transcriptional profiles. A number of axonal signals have been 73	
implicated in the regulation of the Schwann cell phenotype, including ADAM22 which binds 74	
Lgi4 secreted by the Schwann cell and the axonal growth factor neuregulin1 type III (Nrg1III), 75	
which activates the ErbB2/ErbB3 heterodimer on Schwann cells (see (Kidd et al., 2013; Nave 76	
and Werner, 2014; Monk et al., 2015; Salzer, 2015) for recent reviews). 77	
Nrg1, in particular, controls virtually all aspects of the Schwann cell lineage including 78	
initial gliogenesis, proliferation, ensheathment and myelination of axons. High levels of Nrg1III 79	
on the axonal membrane provide a threshold signal for the induction of myelination and 80	
regulate the thickness of the myelin sheath (Michailov et al., 2004; Taveggia et al., 2005; Nave 81	
and Salzer, 2006). Nrg1III activates the Mitogen-activated protein kinase (MAPK), 82	
Phosphatidylinositol 3-kinase 1A (PI3K) and Phospholipase C gamma (PLCγ) pathways, each 83	
of which has been implicated as essential for proper myelination (Newbern and Birchmeier, 84	
2010). The precise roles of these signaling pathways in the transcriptional and morphogenetic 85	
events of myelination however, remain to be established.  86	
Previous studies using in vitro models demonstrated that PI3K activation is necessary 87	
for proper PNS myelination (Maurel and Salzer, 2000; Ogata et al., 2004). A promyelinating 88	
role of PI3K was further supported by studies in mice in which the Phosphatase and tensin 89	
homolog (PTEN), a PI-3 phosphatase, was conditionally inactivated in glia thereby driving 90	
sustained activation of PI3K (Goebbels et al., 2010). Loss of PTEN function in these mice, as 91	
well as inactivation of its interactor Dlg1 (Cotter et al., 2010; Goebbels et al., 2010; Noseda et 92	
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al., 2013) results in PNS hypermyelination and increased wrapping of small caliber axons by 93	
Schwann cells.  94	
The serine/threonine kinase Akt has been thought to be the major PI3K effector during 95	
myelination, particularly in the CNS (Flores et al., 2008). Mice expressing a constitutively 96	
active, phospho-mimetic form of Akt under control of the proteolipid protein (PLP) promoter, 97	
exhibit hypermyelination in the CNS. Surprisingly the PNS of these mice was not 98	
hypermyelinated (Flores et al., 2008) leaving open the question of the role of Akt in Schwann 99	
cells.  100	
Here we use loss and gain of function approaches to provide direct evidence that Akt 101	
promotes PNS myelination and axonal wrapping. Pharmacological inhibition of Akt activity 102	
abrogates myelin formation in vitro, without affecting the levels of Krox20/Egr2, a transcription 103	
factor crucial for PNS myelination (Zorick et al., 1996; Decker et al., 2006). Conversely, mice 104	
that express a myristoylated, constitutively active Akt transgene in myelinating glia under 105	
control of the 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP) promoter, exhibit 106	
hypermyelination in the PNS and CNS. No conversion of axons from an unmyelinated to a 107	
myelinated fate was observed in these mice, although aberrantly, hyperwrapped Remak fibers 108	
are common. These mice also exhibit focal hypermyelination, a pathological hallmark of some 109	
models of peripheral neuropathies (Adlkofer et al., 1997; Bolino et al., 2004; Tersar et al., 2007; 110	
Robinson et al., 2008). They develop myelin defects similar to those described in a model of 111	
tomaculous neuropathy (Goebbels et al., 2012), which can be corrected with rapamycin 112	
treatment. Finally, Akt activation in vitro results in activation of Rac1, previously implicated in 113	
myelin sheath wrapping (Thurnherr et al., 2006; Benninger et al., 2007; Nodari et al., 2007). 114	
Together, these data indicate that Akt promotes Schwann cell wrapping and myelination 115	
via multiple distinct pathways involving mTOR and Rac1 activation. 116	
 117	
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MATERIAL AND METHODS 118	
Generation of the CNP-MyrAkt and CNP-AktDD transgenic mice: 119	
cDNAs for MyrAktHA and HAAktDD were kindly provided by Dr. Thomas Franke (New 120	
York University) (Franke et al., 1995; Matsui et al., 1999). A plasmid containing the CNP 121	
promoter (Gravel et al., 1998) was kindly provided by Dr. Karen Chandross (Sanofi). 122	
CNP-MyrAkt: The vector containing the CNP cassette was digested with BamHI and 123	
dephosphorylated with CIP phosphatase. MyrAktHA was released using BamHI/BglII digestion 124	
and inserted after the CNP promoter. The construct CNP-MyrAktHA was then released by 125	
sequential digestion AseI/BtsI. DNA was purified by gel extraction (QIAquick gel extraction, 126	
Qiagen), salt elution (Elutip-D, Whatman #10462615), and ethanol precipitation. 127	
CNP-AktDD: The vector containing the CNP cassette was digested with AfeI/BamHI. An 128	
initial ClaI digestion followed by Kleenow filling was done in AktDD cDNA. Afterwards, BamHI 129	
digestion was performed. The insert was ligated after the CNP promoter and then released 130	
using AseI/MluI digestion. The DNA was purified as described for the CNP-MyrAktHA 131	
construct. 132	
The constructs were injected into FVB females in the NYUMC Transgenic Mouse Core. 133	
Positive founders were PCR identified over tail DNA using the primers TgAktFd (5'-TCT GAG 134	
GAT GCC AAG GAG AT-3') and TgAktRev (5'-GGG CGA TCG AGT GAA TTG TA-3'). To 135	
ensure the specificity of the PCR product, one of the primers was designed to match a portion 136	
of plasmid inserted with the cassette. Founders were backcrossed to C57Bl6 wild-type mice for 137	
at least five generations before analysis; sibling littermates were used in all analyses. All 138	
experiments were carried out with the L1MyrAkt line, but a similar phenotype was observed in 139	
the L2MyrAkt line. In some cases (AktDD), analysis was done on founders because of 140	
infertility. All experiments with mice were performed in accordance with the legal requirements 141	
of NYU. 142	
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Akt knockouts: Akt1KO (Cho et al., 2001a) and Akt2KO (Cho et al., 2001b) were 143	
obtained from The Jackson Laboratory (stock numbers 004912 and 006966, respectively). 144	
Akt3KO (Easton et al., 2005) were obtained from Dr. Morris J. Birnbaum (University of 145	
Pennsylvania) under MTA agreement. 146	
Materials. Antibodies to specific proteins were obtained from the following companies: 147	
Cell Signaling Technology (total Akt1-3, pAkt Ser473, pAkt Thr308, total c-Jun and p c-Jun 148	
Ser73, total S6RP and pS6RP Ser235/236, total GSK3b and pGSK3b Ser9, rabbit HA), 149	
Millipore (rabbit MBP, chicken P0, chicken MBP, mouse NeuN); Covance (mouse SMI 94 MBP, 150	
chicken Neurofilament), Sigma (mouse tubulin, rabbit anti-EHS laminin, rabbit actin, mouse 151	
HA.11). Rabbit anti-Krox20 and rabbit anti-Oct6 were kindly provided by Dr. Dies Mejer 152	
(University of Edinburg), guinea pig anti-CASPR by Dr. M. Bhat (University of North Carolina) 153	
and guinea pig anti-Oct6 antibody was provided by Dr. Jeremy Dasen (New York University). 154	
Secondary antibodies conjugated to rhodamine, AMCA or Alexa 488 were obtained from 155	
Jackson ImmunoResearch. 156	
Immunoblotting. Tissues were lysed in 2% SDS, 25 mM Tris, 95 mM NaCl and 10 mM 157	
EDTA buffer with protease inhibitors (complete Mini EDTA-free tablets, Roche 11836170001) 158	
and phosphatase inhibitors (PhosSTOP, Roche 04906837001). Nerves were sonicated 10 159	
seconds at the lowest intensity. Fifteen to fifty micrograms of protein was loaded on 12.5% 160	
SDS-PAGE gel. After transfer on nitrocellulose membrane (Whatman #10402580), and 161	
incubation with primary antibodies, the blots were developed and quantified by using infrared 162	
secondary antibodies and software from Odyssey Imager (LI-COR Biosciences). 163	
Lentivirus production and infection: Doxycycline inducible lentiviruses were created in 164	
the pSLIK-Hygromycin vector as per the manufacturer’s instructions (Invitrogen, Gateway 165	
Technology with clonase II). Confluent 293FT cells were lipofected with LipoD293 reagent 166	
(SignaGen laboratories SL 100668). A triple lipofection with Δ8.9 (4 µg), VSVG (6 µg) and 167	
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MyrAkt-HA or green fluorescent protein (GFP) (5 µg) was performed. Supernatant was 168	
collected 48 hours after lipofection and used to infect Schwann cells. Infected cells were 169	
selected for 9 days with 200 µg/ml of hygromycin (Hygrogold, Invivogen # ant-hg-1) prior to use 170	
in experiments. Induction was performed by adding doxycycline (2 µg/ml) to the culture media 171	
for four days. 172	
Dorsal root ganglia neuron-Schwann cell cocultures: Rat neuron-Schwann cell 173	
cocultures were performed as previously described (Taveggia et al., 2005). 174	
Rapamycin and LY294002 (LY) were obtained from LC Laboratories (R-5000 and L-175	
7962 respectively). Perifosine (Pf) was obtained from Cayman Chemical Company (10008112). 176	
Drugs (20 µM of LY294002 or 20 µM of perifosine) were added 24 hours prior to and then 177	
continued after switching the cocultures to myelinating media. 178	
Rac1 and cdc42 pull down: Schwann cells were infected with inducible MyrAkt and 179	
processed as described above. Doxycycline was then added to the proliferative Schwann cell 180	
media for 4 days and Rac1 and cdc42 activities were analyzed as previously described 181	
(Deinhardt et al., 2011). To generate the respective plots, values of active GTPase levels were 182	
divided by the total GTPase levels after actin normalization, which was used as a loading 183	
control. 184	
Cell culture immunofluorescence and immunohistochemistry: Mice were fixed via 185	
transcardial perfusion with 4% PFA. Dissected brains were postfixed in 4% PFA overnight at 4° 186	
C, cryoprotected by immersion in 20% sucrose in PBS. 40 µm floating sections were prepared 187	
on a cryostat. Cells were fixed 15 minutes with 4% PFA. Tissue and cells were processed for 188	
immunostaining as previously described (Zanazzi et al., 2001). For Fig. 4D, adult mouse sciatic 189	
nerve and dorsal root ganglia were fixed in 1% PFA and embedded for cryosectioning and 190	
processed for immunofluorescence.  191	
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Teased fibers: Sciatic nerves were harvested from six-months old animals and fixed in 192	
2% PFA for four hours. After a 10 minute wash in 30 mM glycine PBS, the fibers were teased 193	
on a glass slide using needles, and dried overnight. Slides were kept at -80º C until needed. 194	
Tissue was permeabilized 20 minutes in cold methanol prior to staining as described above. 195	
Then, the same protocol as used for cell staining was followed. 196	
Proliferation assay: 50,000 rat Schwann cells were seeded into established, purified rat 197	
neuron cultures for 24h prior to adding the drugs (Pf and LY) to the media in a final volume of 198	
400 µl. Twenty hours later, cocultures were exposed to media containing the drugs and 20 µM 199	
of bromodeoxyuridine (BrdU) for 4 hours. Cells were then fixed in PFA 4%, permeabilized with 200	
methanol and treated as previously described (Maurel and Salzer, 2000). The ratio of BrdU 201	
positive:Hoechst positive cells were calculated from non-overlapping pictures of the whole 202	
coverslip. Four independent sets of experiments were performed (n=4), and from each of them, 203	
three independent coverslips were screened. 204	
RNA extraction and quantitative real-time PCR: Total RNA was isolated using a 205	
RiboPure Kit (Ambion). cDNA was generated from 250-600 ng of total RNA by AMV Reverse 206	
Transcriptase (Promega) and the transcripts were detected and amplified by quantitative real-207	
time PCR in a LightCycler machine (Roche) following the manufacturer’s instructions. GAPDH 208	
was used as internal control. Real-time PCR conditions were as follows:  1 cycle 10’ 95º C, 50 209	
cycles (30’’ 95º C, 30’’ 56º C, 30’’ 72º C), 1 cycle 1’ 95º C, 30’’ 55º C and 30’’ 95º C.  Primers: 210	
MAG Fd 5’-ACC TTG CAG TTC GAG GGT TA-3’, MAG Rev 5’-ACA GAG CAG GCT GAC ATG 211	
G-3’; MBP Fd 5’-ACT ACC CAC TAC GGC TCC CT-3’, MBP Rev 5’-GGG TGT ACG AGG TGT 212	
CAC AA -3’; Krox20 Fd 5’-GGT GTG TGT ACC ATG TCC CA-3’, Krox20 Rev 5’-CCA GAG 213	
AGG AGG TGG AAG TG-3’; GAPDH Fd 5’-AGA AGA CTG TGG ATG GCC C-3’; GAPDH Rev 214	
5’-TTC AGC TCT GGG ATG ACC TT-3’; MPZ Fd 5’-TCC CTC ATC CAG CCC CAG CC-3’, 215	
MPZ Rev 5’-CTG GGA GCG CAC AGC ACC AT-3’. 216	
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Rapamycin treatment in vivo: The drug was dissolved in vehicle solution containing 5% 217	
polyethylene glycol 400, 5% Tween 80, and 8% ethanol. Rapamycin (7.5 mg/kg) or vehicle was 218	
administered intraperitoneally for 5 days a week during 8 weeks. Mice were treated beginning 219	
at 5 weeks of age and were weighed every week to adjust the treatment. A total of 21 mice 220	
were treated, 7 WT and 7 Tg with vehicle, and 7 Tg with rapamycin. Two independent rounds 221	
of treatment were done for morphometric and WB analyses. 222	
Electronic microscopy and morphometric analysis: Control and treated three weeks old 223	
myelinating cocultures grown on collagen-coated glass coverslips were rinsed in PBS and fixed 224	
overnight at 4° C in 2% glutaraldehyde in 0.1 M phosphate buffer pH 7.0 (0.1 M PB). After 225	
gently removing the fixed cultures from the coverslips they were washed in 0.1 M PB, 226	
incubated in 2% osmium tetroxide in 0.1 M PB for 1 hour and processed for flat embedding in 227	
EMbed 812 (Electron Microscopy Sciences, Fort Washington, PA). Ultrathin sections were 228	
counterstained with uranyl acetate and Reynold's lead citrate and examined on a Philips 229	
(Eindhoven, The Netherlands) CM10 electron microscope. For the in vivo analysis, mice were 230	
fixed via transcardial perfusion with 4% paraformaldehyde, 2.5% glutaraldehyde and 0.1 M 231	
sucrose in 0.1 M PB, pH7.4. Sciatic nerves, spinal roots (L4 level), optic nerve and sympathetic 232	
tract were collected. Tissues embedded in EMbed 812 were sectioned on a Leica UCT 233	
ultramicrotome at a thickness of 1 µm and stained with a solution of 1% toluidine blue. For 234	
TEM, tissues embedded in EMbed 812 were sectioned on a Leica UC6 ultramicrotome at a 235	
thickness of 90 nm and placed on copper slotted grids	or occasionally on mesh grids. Sections 236	
were stained with 3% uranyl acetate in 50% methanol for 20 minutes followed by lead citrate 237	
for 5 minutes. Grids were viewed on a Philips CM12 Tungsten Emission TEM at 120kV and 238	
imaged with a GATAN 4k x 2.7k digital camera.  239	
For g-ratios, non-overlapping digitized images of fiber cross-sections from dorsal roots 240	
were obtained and analyzed using Nikon software. G ratio were calculated by dividing the axon 241	
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diameter by the total fiber diameter. G ratios were determined exclusively in the dorsal root due 242	
to their mix of small and large caliber axons. All fibers with myelin abnormalities or fixation 243	
artifacts were excluded from analysis. Three animals per genotype were used for the 244	
WT/MyrAkt data (Fig. 5D, E), and four animals per genotype and conditions were quantified for 245	
the rapamycin experiments (Fig. 9D). The number of axons per Remak bundle and the number 246	
of axons in Schwann cell pockets were counted in the sciatic nerve by using Image J software 247	
(National Institute of Health). The number of axons per 100 µm2 and the total number of myelin 248	
abnormalities per sciatic nerve were determined from merged micrographs of thin sciatic nerve 249	
sections (400X), assembled with Adobe Photoshop (Fig. 9C). Overlapping digitized images 250	
(400X) from thin sections of dorsal and ventral roots were merged to determine the total 251	
number of myelinated axons in Fig. 6F. 252	
Statistical analysis: The unpaired two-tailed T-test was performed on all data to assess 253	
significance. In each case, the standard error of the mean (SEM) is shown in the plots although 254	
only the upper part of the SEM is depicted. Each n represents a different independent 255	
experiment or animal. Significance was considered for p < 0.05 (*) and p < 0.01 (**). 256	
 257	
RESULTS 258	
Akt activity is required for myelination and axon sorting  259	
To address a role of Akt in myelination, we first examined Akt null mice for any 260	
abnormalities in the peripheral nerves. There are three Akt genes (Akt1, Akt2 and Akt3), each 261	
with different tissue expression and substrate affinities (Easton et al., 2005; Tschopp et al., 262	
2005; Franke, 2008; Leavens et al., 2009). Western blot analysis revealed that Akt1 is 263	
expressed in both neurons and Schwann cells whereas Akt2 and Akt3 are primarily expressed 264	
by Schwann cells and neurons, respectively (Fig. 1A). We next examined whether mice 265	
deficient in each of these Akt isoforms exhibit myelination defects by comparing sciatic nerves 266	
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from two month-old WT vs. knockout mice via semithin sections. There were no obvious 267	
differences between the knockout mice and their wild type littermates in terms of nerve size or 268	
the extent of myelination (Fig. 1B). No obvious abnormalities of myelinated fibers or Remak 269	
bundles were evident on inspection of electron micrographs of the Akt mutants vs. their WT 270	
littermates (Fig. 1Ba-f). The overall preservation of morphology in individual mutants likely 271	
reflects compensation by remaining Akt isoforms. 272	
We therefore undertook to inhibit all Akt activity with the pharmacological inhibitor 273	
perifosine (Pf), an alkylphospholipid that impairs Akt by blocking its PH domain (Hennessy et 274	
al., 2007; Gills and Dennis, 2009). In parallel, we inhibited PI3K activity with the LY294002 (LY) 275	
inhibitor (Vlahos et al., 1994; Maurel and Salzer, 2000). Treatment of cocultures with each 276	
inhibitor blocked nearly all myelin formation (Fig. 2A, B). In agreement, expression levels of 277	
MBP and P0 protein (Fig. 2C, D) were significantly reduced in the Pf-treated and nearly absent 278	
in the LY-treated cocultures. mRNA levels for MBP were dramatically reduced in the presence 279	
of either drug whereas the effect of Pf on P0 was more modest, perhaps due to its higher basal 280	
levels of expression (Fig. 2E). Unexpectedly, Oct6/SCIP and Krox20, key transcription factors 281	
for PNS myelination, were robustly expressed in the nuclei of the Pf-treated Schwann cells 282	
(Fig. 2A) and the levels of Krox20 protein (Fig. 2C, D) and mRNA (Fig. 2E) were unaffected. 283	
These results suggest that the promyelinating effects of Akt are independent of Krox20. In 284	
contrast to Pf, cocultures treated with LY did not express any Krox20 protein or mRNA (Fig. 2A, 285	
C-E). 286	
There was no effect of Pf on Schwann cell proliferation in the cocultures (Fig. 2F), in 287	
further contrast to LY  (Fig. 2F), which is known to inhibit Schwann cell proliferation induced by 288	
axonal neuregulin (Maurel and Salzer, 2000). Consequently Schwann cell numbers were 289	
markedly reduced in the LY- but not the Pf-treated cocultures (Fig. 2A). To determine whether 290	
reduced numbers of Schwann cells in the LY treated cocultures contributed to the limited 291	
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expression of Krox20, we seeded a 5 fold excess of SCs prior to treatment with LY. No 292	
significant Krox20 or myelin protein expression was detected under these conditions (data not 293	
shown) indicating that the effects of LY are independent of an effect on cell numbers. 294	
Our results confirm that PI3K activity is crucial for myelination in vitro and reveal that its 295	
effector Akt controls myelin mRNA and protein expression in the PNS, independent of Krox20 296	
regulation. The data also suggests that PI3K regulates Schwann cell proliferation and the 297	
expression of myelin transcription factors by mechanisms independent of Akt. 298	
Ultrastructural analysis of these cultures further revealed that Pf and LY differentially 299	
affected Schwann cell ensheathment. Schwann cells in the Pf-treated cultures partially 300	
surrounded the axons, although did not completely wrap most of them (Fig. 2G). In contrast, in 301	
the LY treated cocultures, Schwann cell were apposed to but completely failed to ensheathe 302	
axons (Fig. 2G). Myelination was dramatically reduced by both treatments. 303	
Activated Akt enhances myelin protein and mRNA expression in vitro independent of 304	
Krox20 levels  305	
We next examined whether Akt activity is not only necessary, but is also sufficient for 306	
triggering myelination. We used a lentiviral vector to express a doxycycline-inducible, HA-307	
tagged myristoylated Akt (MyrAkt) in cultured Schwann cells. MyrAkt is expressed and active at 308	
the membrane independent of PIP3 concentrations. After infection, Schwann cell cultures were 309	
maintained on media containing ascorbate in the presence or absence of doxycycline for four 310	
days. Schwann cells infected with a doxycycline-inducible lentivirus encoding GFP, which 311	
served as a control, displayed no increase of myelin proteins or Krox20 (Fig. 3A). In general, 312	
the expression of activated Akt increased MAG and P0 protein and mRNA levels; this increase 313	
was significant in the case of MAG protein (Fig. 3B-D). Interestingly, Krox20 protein levels were 314	
slightly reduced and mRNA levels unchanged despite the induction of myelin proteins following 315	
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MyrAkt expression (Fig. 3B-D) suggesting these changes were independent of Krox20 316	
regulation. 317	
 318	
Transgenic expression of activated Akt isoforms results in PNS hypermyelination 319	
To assess the role of Akt in vivo, we generated transgenic mice expressing HA-tagged 320	
MyrAkt or AktDD in myelinating glia under control of 2’, 3’-cyclic nucleotide 3’-321	
phosphodiesterase (CNP) promoter elements (Fig. 4A). Both Akt1 isoforms are constitutively 322	
active as the result of either being targeting to the membrane (MyrAkt) or via mutations of two 323	
phosphorylation sites (Thr308 and Ser473) to aspartate that mimic the activated state (AktDD) 324	
(Fig. 4A). We generated four CNP-MyrAkt positive founders and three transgenic CNP-AktDD 325	
founders. All four CNP-MyrAkt lines exhibited enlarged brains, optic and sciatic nerves; this 326	
was evident at several months of age and quite pronounced at one year of age (Fig. 4C). Due 327	
to breeding problems with the CNP-AktDD mice, only founders were analyzed. Only one of the 328	
CNP-AktDD founder mice exhibited a hypermyelinated phenotype, evident in the sciatic nerves 329	
(Fig. 5B).  330	
Two of the CNP-MyrAkt that transmitted the transgene were analyzed in detail. In each 331	
case, transgenic mice were phenotypically indistinguishable from wild type littermates until 332	
approximately one year of age when they developed limited motility and breathing difficulties. In 333	
agreement with the expression of CNP (Chandross et al., 1999), the HA-tagged transgene was 334	
detected in transgenic sciatic nerves at P0.5, the earliest time point examined (Fig. 4B). Its 335	
expression increased during active myelination (P10 to P21) and remained robust into 336	
adulthood. Expression of the HA-tag was also detectable in DRGs directly isolated from E13.5 337	
embryos (Fig. 4B), likely reflecting the presence of glial/satellite cells in these DRGs. In 338	
agreement, staining of adult DRGs and sciatic nerves was largely if not exclusively confined to 339	
glial cells (Fig. 4D). 340	
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Transgenic mice were hypermyelinated in both the CNS and PNS. CNS 341	
hypermyelination was evident by increased MBP staining on coronal sections and an increase 342	
in the size of the corpus callosum (Fig. 4E). Both the sciatic and optic nerves were also 343	
markedly expanded in diameter, based on toluidine blue staining of semi-thin sections (Fig. 344	
5A). Electron micrographs showed that individual nerve fibers were hypermyelinated (Fig. 5B) 345	
evident as an increase in the number of myelin lamellae; myelin periodicity was unaffected (Fig. 346	
5C). G-ratios were significantly decreased in 5 month-old transgenic mice (Figs. 5D, E). 347	
Hypermyelination was most pronounced in small caliber axons, i.e. those less than 2 microns in 348	
diameter in both the dorsal roots (Fig. 5D, E) and ventral roots (data not shown). 349	
The total numbers of Hoechst positive cells in the ventral and dorsal roots were 350	
counted. No significant differences in cell numbers were detected in four transgenic roots as 351	
compared to roots from their WT littermates (Fig. 5F). These results suggest that in our system, 352	
tissue hypertrophy results from an Akt-mediated increase in myelin and, perhaps, increased 353	
extracellular matrix production, rather than increased numbers of cells. 354	
 355	
Akt activation promotes Schwann cell wrapping but does not alter the ensheathment 356	
fate of axons 357	
Remak fibers were also affected in the CNP-MyrAkt transgenic mice. In wild type nerves 358	
as expected, small caliber axons were enclosed within individual pockets of a single 359	
unmyelinated Schwann cell (Fig. 6A). In contrast, in the transgenic nerves, multiple layers of 360	
Schwann cell membrane frequently wrapped small caliber axons. High power micrographs 361	
revealed these wrapped membranes were non-compacted (inset in 6A, middle panel); pockets 362	
with a normal structure that enclosed axons were absent (Fig. 6AI). Transgenic Schwann cell 363	
pockets sometimes contained collagen fibers rather than axons; these were more frequent in 364	
older animals and were surrounded by basal lamina (Fig. 6AII). Indeed, Schwann cell 365	
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processes were also seen surrounded by basal lamina without any axonal contact suggesting 366	
that Akt can drive Schwann cell basal lamina formation in the absence of axonal signals (Fig. 367	
6BI). Some pockets were formed even without any detectable content (Fig. 6BII) and, in such 368	
cases, a reversed orientation of the basal lamina was detected, secreted inside the empty 369	
pocket (Fig. 6BII). Finally, there was a trend to enhanced segregation of unmyelinated axons. 370	
This was evidenced by an increase in transgenic Remak bundles that enclosed just one to five 371	
axons (quantified in Fig. 6C) or with single-axon pockets (Fig. 6D) compared to WT bundles. 372	
We also asked whether Akt activation is sufficient to convert unmyelinated, post-373	
ganglionic sympathetic nerve fibers to a myelinated fate, akin to the effects of overexpressing 374	
Nrg1III in these axons (Taveggia et al., 2005). Examination of the sympathetic tract of 375	
transgenic mice (Fig. 6E) revealed that fibers were consistently unmyelinated. Instead, multiple 376	
layers of Schwann cell membrane surrounded the axons thus resembling the Remak bundles 377	
in the sciatic nerves and dorsal roots of the transgenic mice. Schwann cell pockets containing 378	
only extracellular matrix were also found in this tract (Fig. 6E). 379	
In agreement with a lack of effect on myelination, the proportion of myelinated fibers in 380	
the dorsal and ventral roots of transgenic and wild type mice were comparable (Fig. 6F). 381	
Together, these data suggest that Akt regulates axonal wrapping and that other signals are 382	
required for myelination. 383	
 384	
MyrAkt specifically enhances Rac1 activity in Schwann cells  385	
Rac1 and cdc42 are crucial for proper sorting of axons at early stages of myelination; 386	
their precise roles differ as cdc42 controls the pool of Schwann cells by affecting proliferation 387	
whereas Rac1 induces radial lamellopodia required to sort axons (Benninger et al., 2007; 388	
Nodari et al., 2007). To assess whether the enhanced axonal sorting and wrapping observed in 389	
MyrAkt animals might reflect activation of Rac1 or cdc42, we induced MyrAkt in cultured 390	
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Schwann cells. Induction of Akt led to activation of Rac1 but not cdc42 based on pull-downs 391	
with GST-Pak1 (Fig. 7A, B); there was no change in total levels of either Rac1 or cdc42. This 392	
data suggests that part of the phenotype observed in the transgenic mice, such as enhanced 393	
Schwann cell sorting, is a consequence of increased Rac1 activity. 394	
 395	
Transgenic nerves develop tomacula and myelin outfoldings/infoldings 396	
A consistent finding in the MyrAkt sciatic nerves was the presence of numerous myelin 397	
abnormalities. These included myelin outfoldings, a histological hallmark of some Charcot-398	
Marie-Tooth (CMT) forms, notably CMT4B (Bolis et al., 2005; Tersar et al., 2007), and 399	
tomacula, i.e. focal thickenings of the myelin sheath characteristic of Hereditary Neuropathy 400	
with Liability to Pressure Palsies (HNPP) (Adlkofer et al., 1997); tomacula were also seen in the 401	
PTEN conditional knockout mice (Goebbels et al., 2012). Five month-old nerves developed 402	
mostly myelin infoldings (Fig. 8A, left panel, and Fig. 8BII) and tomacula (Fig. 8A, right panel, 403	
and Fig. 8BI). These changes were preferentially located to regions of non-compacted myelin, 404	
i.e. the paranodes and Schmidt-Lanterman incisures. Tomacula were accompanied by axonal 405	
compression at the affected regions, although no axonal degeneration was detected at the 406	
ages examined (up to one year old). Other abnormalities such as myelin outfoldings were 407	
observed in a lower proportion of cases (Fig. 8BIII, C). Teased fibers from transgenic sciatic 408	
nerves also revealed presumptive tomacula, which were either symmetric (both sides of the 409	
affected node) or asymmetric (only one side affected, e.g. Fig. 8D). Similar asymmetry of 410	
hypermyelination was also observed (data not shown). 411	
 412	
Rapamycin treatment prevents myelin abnormalities in vivo 413	
The mTOR pathway has been previously implicated in the Akt-mediated 414	
hypermyelination in the CNS (Flores et al., 2008; Narayanan et al., 2009; Goebbels et al., 415	
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2010) and PNS (Goebbels et al., 2012; Sherman et al., 2012; Norrmen et al., 2014). In 416	
agreement, MyrAkt activates mTOR in the PNS based on Western blot analysis of sciatic nerve 417	
lysates. Increased phosphorylation of Akt at both the S473 or Th308 residues was readily 418	
detected in the transgenics by the appearance of an extra phosphorylated Akt band resulting 419	
from the myristoylation tag (Fig. 8E). A statistically significant increase of phospho-S6RP 420	
(S235/236) levels, an indirect substrate of mTORC1 and readout of Akt activation, was found in 421	
samples from transgenic animals when compared to their wild type littermates (Fig. 8E, F). The 422	
levels of phospho-GSK3b (S9) and the translation repressor protein phospho-4E-BP1 423	
(Thr37/46) were also increased in those nerves, although did not reach statistical significance. 424	
No significant differences were found for the total levels of any of these proteins (Fig. 8F). 425	
These results confirm that the CNP-MyrAktHA transgene is not only properly expressed, but 426	
also active in those animals. 427	
Treatment with rapamycin for eight weeks resulted in a dramatic reduction in sciatic 428	
nerve size in MyrAkt mice (Fig. 9A, C) and a correction of hypermyelination (Fig. 9A). The 429	
efficacy of the rapamycin treatment on mTOR activity was corroborated by Western blot 430	
analysis (Fig. 9B). Other parameters affected in the MyrAkt transgenics, such as brain size or 431	
the number of myelin abnormalities, were also ameliorated by rapamycin treatment, and 432	
corrected to near wild type levels (Fig. 9C). In dorsal roots, g-ratios values were significantly 433	
increased in drug-treated versus vehicle-treated transgenics (0.59 +/- 0.02 and 0.54 +/- 0.01 434	
respectively), although the values were still somewhat lower than their wild type littermates 435	
(0.62 +/- 0.006, Fig. 9D). Interestingly, no improvement of the hyperwrapping phenotype was 436	
detected in the Remak bundles of the rapamycin-treated transgenics (Fig. 9E). Taken together, 437	
our data indicates that mTOR activation has a key role in many but not all of the PNS 438	




PNS myelination is controlled by levels of axonal NRG1III (Michailov et al., 2004; 442	
Taveggia et al., 2005), which activates Schwann cell ErbB receptors and thereby PI3K, MAPK, 443	
and Phospholipase C-γ; each of these pathways have been implicated in myelination (Pereira 444	
et al., 2010; Pereira et al., 2012; Salzer, 2015). In the case of PI3K, pharmacological inhibition 445	
blocks myelination in vitro at an early stage (Maurel and Salzer, 2000) whereas PI3K gain of 446	
function, via conditional ablation of PTEN, results in hypermyelination in vivo with the 447	
occasional small caliber axon switching to a myelinated fate (Goebbels et al., 2010). The 448	
serine/threonine kinase Akt is a major effector of PI3K and is thus a candidate to mediate these 449	
effects in the PNS. However, a prior study of a transgenic mouse overexpressing Akt-DD in 450	
both oligodendrocytes and Schwann cells under the control of the glial promoter PLP, 451	
demonstrated hypermyelination in the CNS but not the PNS (Flores et al., 2008). This latter 452	
result raised the question of whether the effects of PI3K in the PNS are primarily mediated by 453	
Akt or result from Akt-independent signaling by PI3K (Ebi et al., 2013). 454	
We now demonstrate that Akt is indeed a key regulator of PNS myelination based on 455	
both loss (perifosine treatment) and gain of function (transgene) analyses. The expression of a 456	
constitutively active Akt under control of the CNP promoter provides some striking similarities 457	
and interesting differences with previously reported animal models. In particular, our findings 458	
phenocopy important aspects of the PTEN conditional mice (Goebbels et al., 2010; Goebbels 459	
et al., 2012), while differing from the prior Akt transgenic mouse model (Flores et al., 2008). 460	
CNP comprises a higher percent of the total myelin protein in the PNS than does PLP (Patzig 461	
et al., 2011) indicating that the lack of a PNS effect in the previously reported PLP-AktDD 462	
transgenic mice (Flores et al., 2008) may be due to lower expression levels. In addition, we 463	
observed a more consistent hypermyelinating phenotype in the MyrAkt than in the Akt-DD 464	
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transgenics, each under the control of the CNP promoter, suggesting the membrane-targeted 465	
form of Akt is more potent in promoting hypermyelination.   466	
The promyelinating effect of Akt shown here is consistent with evidence that axonal 467	
NRG1III is the main driver of Akt activation (Taveggia et al., 2005; Heller et al., 2014).  Indeed, 468	
overexpression of NRG1III also results in hypermyelination (Michailov et al., 2004) and our 469	
results suggest Akt activation likely strongly contributes. Myelin outfolding/infoldings are also 470	
present in human mutations of MTMR13 in CMT patients and corresponding mouse models, 471	
that increase the levels of PIP4,5 (Bolis et al., 2005; Tersar et al., 2007; Robinson et al., 2008; 472	
Goebbels et al., 2012) which would not be expected to activate PI3K. Thus, other mechanisms 473	
can contribute to myelin outfoldings and tomacula in addition to hyper-activation of Akt. 474	
Interestingly, myelin outfoldings are normally present in the CNS at the peak of myelination as 475	
a consequence of active myelin production, correlated with an elevated concentration of PIP3 476	
at the inner tongue of the process and the presence of cytoplasmic channels (Snaidero et al., 477	
2014). These features disappear in mature CNS myelin. 478	
Here we implicate Akt as a direct regulator of axonal sorting and wrapping, which are 479	
among the earliest events in axon-Schwann cell interactions. Thus, pharmacological reduction 480	
of Akt activity partially blocks wrapping (Fig. 2G) whereas MyrAkt leads to excessive wrapping 481	
in the transgenics, most evident in non-myelinating Schwann cells of Remak bundles and 482	
sympathetic fibers. A similar phenotype was also seen in PTEN conditional mice (Goebbels et 483	
al., 2010). A plausible candidate to mediate these effects is Rac1, which drives generation of 484	
radial lamellopodia in Schwann cells required for ensheathment of axons and the onset of 485	
myelination (Benninger et al., 2007; Nodari et al., 2007). PI3K activates its effectors, including 486	
Akt, by generating local concentrations of PIP3. PI3K similarly activates Rho GTPases, notably 487	
Rac, via PIP3-dependent activation of members of the Dbl family of guanine-nucleotide 488	
exchange factors (GEFs) (Innocenti et al., 2003). Results in this study (Fig. 7) indicate that Akt 489	
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can activate Rac1 independently of PIP3-dependent effect of PI3K on GEFs. They further 490	
suggest Akt-dependent activation of Rac1 may account for the hyperwrapping and 491	
hypermyelination observed in the PTEN conditional mice given the similarity of phenotypes. 492	
Interestingly, the membrane outfoldings and Schwann cell pockets induced by MyrAkt 493	
were not obligately coupled to axonal contact; even collagen fibers were wrapped in the 494	
transgenic mice (Fig. 6AII). In normal nerves, Akt is activated initially along the internode, in 495	
close apposition to and dependent on NRG on the axon; activated Akt is later detected at the 496	
paranodes once compact myelin has formed (Heller et al., 2014). The NRG-dependent 497	
activation of Akt locally, along the inner turn, thus favors specific wrapping of the apposed 498	
axon. In contrast, the widespread activation of Akt along other membranes of the transgenic 499	
Schwann cells, likely supports wrapping that is independent of axonal contact.  Remarkably, 500	
some of the Schwann cell processes lacking axonal contact were surrounded by basal lamina 501	
in the transgenics (Fig. 6A, B). These results suggest that Akt may help transduce the axonal 502	
signal that drives production and deposition of extracellular matrix components by Schwann 503	
cells (Bunge et al., 1986). 504	
 A striking result of this study is that the promyelinating effects of Akt are not correlated 505	
to the levels of Krox20, the key transcriptional driver of PNS myelination (Topilko et al., 1994). 506	
Thus, induction of MyrAkt in Schwann cell cultures resulted in an increase, with some 507	
variability, of myelin protein and mRNA levels despite a modest reduction in the basal levels of 508	
Krox20 (Fig. 3). Conversely, inhibition of Schwann cell Akt by Pf partially arrests ensheathment 509	
and nearly completely blocks myelin protein expression but not the upregulation of Oct6 and 510	
Krox20 (Fig. 2). In the latter case, partial ensheathment of axons may have been sufficient to 511	
upregulate these transcription factors whereas treatment with LY by completely abolishing 512	
ensheathment, may have thereby blocked Oct6 and Krox20 expression. Together, these 513	
results suggest that changes in myelin mRNA and protein levels resulting from Akt 514	
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inhibition/activation may not be transcriptionally regulated. Alternative possibilities include an 515	
effect of Akt on miRNAs or protein translation. Akt has been implicated in regulating miRNA 516	
levels via the FOXO transcription factors and MDM2/p53 activity (Xu and Mo, 2012); FOXO 517	
phosphorylation is indeed increased in the MyrAkt mice (E. Domènech-Estévez, data not 518	
shown) raising the potential of similar regulation of the Schwann cell phenotype via miRNAs 519	
(Pereira et al., 2010). In addition, Akt may control myelin protein levels by regulating their 520	
turnover and translation. A key role for translational control in myelination was shown by the 521	
rescue of myelination in ErbB deficient Schwann cells via expression of activated Mek1DD 522	
which, in turn, strikingly upregulated protein translation (Sheean et al., 2014). Like the MyrAkt 523	
transgenics, sciatic nerves in the activated Mek1 transgenic mice are hypermyelinated, with 524	
tomacular defects, and have small caliber axons that remain unmyelinated (Sheean et al., 525	
2014). This latter result suggests that other signaling pathways downstream of NRG/ErbB 526	
activation, including the PLCγ/calcineurin/NFATc4 pathway (Kao et al., 2009), are also required 527	
for expression of the transcriptional phenotype of myelinating Schwann cells. 528	
As in the PTEN mutants, the MyrAkt transgenics have increased mTORC1 activity, 529	
evidenced by increased phosphorylation of S6RP (Fig. 8). mTOR has a key role in Schwann 530	
cell myelination (Sherman et al., 2012). In particular, the mTORC1 complex links nutrient 531	
availability and cell growth by regulating protein and lipid synthesis (Porstmann et al., 2008; 532	
Laplante and Sabatini, 2009; Peterson et al., 2011). Mice deficient in the mTORC1 component 533	
raptor have delayed myelination and hypomyelination in the adult due to impaired RXRγ-534	
SREBP controlled lipid biosynthesis (Norrmen et al., 2014); these results place mTORC1, and 535	
by implication Akt, as important coordinators of protein translation and lipid synthesis in the 536	
myelinating Schwann cells. Rapamycin administration dramatically reduces the pathological 537	
features of the MyrAkt transgenics, normalizing the g-ratios, number of axons per area, number 538	
of myelin abnormalities and brain weight (Fig. 9). These results corroborate the beneficial 539	
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effects of rapamycin in treating dysmyelinating pathologies resulting from deregulation of the 540	
PI3K-Akt-mTORC1 axis (Narayanan et al., 2009; Goebbels et al., 2012).  541	
Interestingly, the hyperwrapping phenotype in the transgenics in unmyelinated Schwann 542	
cells was not blocked by rapamycin (Fig. 9E), presumably as hyperwrapping is driven by Rac1 543	
and is independent of mTOR. Thus, Akt-induced wrapping and myelin production, although 544	
coordinated, are two distinct phenomena driven by independent pathways. Indeed, multiple 545	
crucial events of myelination, including morphogenesis (Benninger et al., 2007; Ozcelik et al., 546	
2010), transcriptional activation (Zorick et al., 1996; Jacob et al., 2011), protein and lipid 547	
synthesis (Nadra et al., 2008; Norrmen et al., 2014) and metabolic status (Pooya et al., 2014) 548	
must all be tightly coordinated during Schwann cell myelination. Akt activation likely contributes 549	
to each of these events with the potential exception of Krox20-dependent transcriptional 550	
events. 551	
In conclusion, we have shown that Akt has a key role in regulating PNS myelination, 552	
enhancing membrane wrapping potentially via Rac1 activation and myelin protein synthesis via 553	
mTORC1. These studies suggest that PI3K/Akt activation has a key role and cooperates with 554	
other signaling pathways during the shift from the ensheathing to the myelinating Schwann cell 555	
phenotype. Our data additionally suggest that myelin abnormalities in various neuropathies, 556	
including in/outfoldings and tomacula, may result from Akt activation and highlight Akt and its 557	
effectors, as potential therapeutic targets. Akt activation would be expected to ameliorate the 558	
phenotype of hypomyelinating peripheral neuropathies, e.g. CMT4C (Arnaud et al., 2009; 559	
Gouttenoire et al., 2013) whereas Akt inhibition would be a candidate to ameliorate tomacular 560	
defects in neuropathies such as HNPP (Sander et al., 2000; Goebbels et al., 2012). Further 561	
studies of Akt-dependent pathways in myelination may identify more specific therapeutic 562	
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 Figure 1. Loss of individual Akt isoforms in vivo does not affect PNS myelination.  771	
A, Western blot analysis of the expression of the three Akt isoforms in dorsal root ganglia 772	
neurons (Neu), Schwann cells (SC), and non-myelinated (C) or myelinated (C+C) cocultures. 773	
Akt1 and Akt3 are preferentially expressed by neurons whereas Akt2 is primarily expressed by 774	
Schwann cells. n=3. SEM is shown. B, Semithin sections of sciatic nerves from two month-old 775	
mice deficient in each Akt isoform revealed no obvious defects of myelination. Left panels show 776	
a magnification of the inset from the semithin section. Right panels (a-f) show representative 777	
images of Remak bundles. No abnormalities of myelination or ensheathment were evident at 778	
the time point analyzed, although no quantifications were performed. Scale bars for semithin 779	
100 µm, for EM 2 µm. 780	
 781	
Figure 2. Akt inhibition blocks myelin formation in vitro without affecting Krox20 levels.  782	
A, Treatment of DRG neuron-Schwann cell cocultures with perifosine (Pf) or LY294002 (LY) 783	
blocked myelination. The myelin transcription factors Krox20 and Oct6 continue to be robustly 784	
expressed by Schwann cells in the Pf but not the LY treated cocultures. n=5, four coverslips 785	
were analyzed for each n. B, Quantification of the blockade of myelination by Pf and LY. The 786	
average number of myelin segments per coverslip were: controls, 2195; Pf, 37 (p=0.0056); and 787	
LY, 3 segments (p=0.005). n=3, each n represents two coverslips. C,D, Pf treated cells showed 788	
no change in Krox20 protein expression (102.8 +/- 12.31, p=0.83), although a significant 789	
decrease in pAkt 473 (40.1 +/- 7.77, p=0.001), MBP (3.1 +/- 0.2, p<0.001) and P0 (12.5 +/- 790	
4.49, p<0.001) was detected. The same markers were also downregulated in LY treated 791	
cocultures (pAkt 26.7 +/- 6.84, p<0.001; MBP 1.6 +/- 1.03, p<0.001; P0 1.69 +/- 0.68, p<0.001), 792	
but in this case Krox20 was also decreased (22.1 +/- 5.86, p<0.001) (n=3, each n represents 793	
eight coverslips pooled per condition). Western blot quantification data were normalized using 794	
	 34	
values from control cocultures that were arbitrarily set to 100. E, As detected by real time PCR, 795	
Pf treated cells showed no changes in Krox20 mRNA (1.27 +/- 0.39, p=0.51), and a significant 796	
decrease of mRNA for MBP (0.13 +/- 0.03, p<0.001). A decrease of P0 was also detected, 797	
although it did not reach statistical significance (0.62 +/- 0.18 p=0.09). These three markers 798	
where significantly downregulated in LY treated cocultures (Krox20 0.12 +/- 0.04, p<0.001; 799	
MBP 0.01 +/- 0.003, p<0.001; P0 0.23 +/- 0.06, p<0.001). Expression data was normalized to 800	
control samples that were arbitrarily set as 1; GAPDH expression was used as reference. n=4, 801	
four coverslips were pooled per condition for each n. F, Schwann cell proliferation was not 802	
affected by 20 µM of Pf (11.9 +/- 0.019 vs Control 11.2 +/- 0.02), whereas proliferation was 803	
almost absent with 20 µM of LY treatment (0.7 +/- 0.002, p=0.003). n=4, each n represents 804	
three coverslips per condition. G, EM analysis of control, Pf and LY treated cultures revealed 805	
drug-specific differences. In the presence of Pf, Schwann cells (SC) engaged axons (A) and 806	
partially but incompletely sorted them and failed to myelinate. LY treated Schwann cells 807	
completely failed to sort axons. The image depicts representative fields from the cultures 808	
shown in A. Scale bars: 1 µm. SEM is shown in all panels. 809	
 810	
Figure 3. Akt activation promotes myelin formation independently of Krox20 regulation. 811	
Purified Schwann cells infected with doxycycline (Dox) inducible lentiviruses encoding MyrAkt-812	
HA or GFP were cultured in ascorbic acid containing media in the absence of axons. A, GFP 813	
induction with Dox did not affect the basal levels of protein for Krox20, P0 and MAG. Basal 814	
levels for MAG were not detectable for quantification. n=3. B, C Induction of MyrAkt 815	
substantially increased P0 protein levels (358.1, 586.7 and 1114.5 folds vs 100, average 686.5 816	
+/- 223.98, p=0.058) and significantly increased MAG levels (3541.7, 9467.8 and 6717.2 folds 817	
vs 100, average 6575.6 +/- 1712.19, p=0.045), as detected by Western blot. Interestingly, a 818	
modest but significant reduction of Krox20 was also detected (83.8 +/- 5.28, p=0.037). Western 819	
	 35	
blot quantification data were normalizing by using values from control samples that were 820	
arbitrarily set to 100. n=3. SEM is shown. D, Krox20 mRNA expression remained unchanged 821	
(0.77 +/- 0.19, p=0.27) when Akt was induced with doxycycline. mRNA for P0 and MAG were 822	
increased when Akt was induced, although due to the variability of induction (P0 1.7, 3.5 and 823	
1.9 folds versus 1, average 2.4 +/- 0.57, p=0.07, and MAG 17.9, 168.9 and 42.2 folds versus 1, 824	
average 76.3 +/- 46.81, p=0.18) compared to the non-induced, the increase in these markers 825	
did not achieve significance by the T-test. Real time PCR data were normalized by using 826	
values from control samples that were arbitrarily set to 1. GAPDH was used as a reference. 827	
n=3. SEM is shown. 828	
 829	
Figure 4. Constitutively active Akt promotes CNS and PNS hypermyelination.  830	
A, Scheme illustrating the two constitutively active Akt1 constructs driven by the CNP promoter 831	
that were used to establish transgenic mice. B, The HA-tagged construct was weakly 832	
detectable in E13.5 dorsal root ganglia isolated from transgenic mice and readily detectable in 833	
sciatic nerves (SN) from P0.5 until adulthood, with a peak at P10 that correlates with active 834	
myelination. C, One-year-old transgenic mice carrying the MyrAkt transgene developed 835	
enlarged neural structures. Optic nerves (asterisk indicates the optic chiasm), brains, and 836	
sciatic nerves were all enlarged. D, HA was detectable in satellite cells from 2 month-old 837	
mouse dorsal root ganglia without any obvious presence in neurons. In 2 month-old sciatic 838	
nerves, HA was present with variable intensity in Schwann cells. Scale bars 20 µm. E, Four 839	
month-old transgenic brains (MyrAkt) were bigger than wild types (WT), with a thicker corpus 840	
callosum (delineated in blue) and increased MBP staining, evidence of enhanced myelination. 841	
Scale bar 1 mm. 842	
 843	
Figure 5.  Nerves from transgenic mice are hypermyelinated. 844	
	 36	
A, At five months, sciatic and optic nerves from MyrAkt transgenics were enlarged compared to 845	
wild types (WT) mice, as seen in transverse, toluidine blue stained sections (scale bar 100 µm). 846	
B, EM sections show thicker myelin sheaths in 5 month-old MyrAkt and AktDD sciatic nerves. 847	
Optic nerves from MyrAkt were also hypermyelinated. Scale bar: sciatic nerve 10 µm, optic 848	
nerve 2 µm. C, The myelin sheaths in transgenic nerves had increased numbers of myelin 849	
lamellae, scale bar 1 µm; higher magnification revealed no change in the periodicity of the 850	
myelin lamellae, scale bar 100 nm. D, g-ratio analysis revealed hypermyelination was more 851	
pronounced in small caliber axons (0.5 to 2 microns).  E, Average g-ratio in the transgenic 852	
dorsal root was lower than in wild types (0.62 +/- 0.01 vs 0.67 +/- 0.01 respectively, p=0.02). 853	
250 - 300 axons between 0.5 to 8 microns were measured. This difference was accentuated 854	
when only small caliber axons (0.5 to 2 microns) were considered (0.52 +/- 0.004 vs 0.61 +/- 855	
0.01, p=0.002). n=3. SEM shown. F, The numbers of Schwann cell nuclei were comparable in 856	
WT and MyrAkt dorsal roots (216 +/- 9.7 vs 250 +/- 29.2, respectively) and ventral roots (82 +/- 857	
5.5 vs. 94 +/- 8.1, respectively) from 5 months old animals. n = 4. SEM is shown. 858	
 859	
Figure 6. Activated Akt enhances wrapping and sorting but not myelination of axons in 860	
Remak Schwann cells.  861	
A, EM micrographs from 20 month-old mice reveal aberrant axon-Schwann cell relationships in 862	
Remak bundles in transgenic compared to WT mice. Small axons were often surrounded by 863	
circumferential layers of uncompacted Schwann cell membranes (I, shown at higher 864	
magnification in insert). Schwann cell membranes surrounding collagen fibers (II) were also 865	
present in the transgenic nerves and were frequently covered by basal lamina. Scale bar 1 µm 866	
B, In 5 month old-mice, Schwann cell processes (I), with associated basal lamina without 867	
apparent axonal contact are present; arrowheads demarcate basal lamina deposition. Schwann 868	
cells also formed empty pockets with basal lamina deposited in the interior (II arrow in the 869	
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insert); scale bars 2 µm. C, Bar graph showing the distribution of the numbers of axons per 870	
Schwann cell; Remak bundles with only a few axons (1-5) are increased in the 5 month-old 871	
transgenic mice. D, The number of axons per pocket was also decreased in the 5 month-old Tg 872	
suggesting better segregation of axons (one axon per pocket WT 89.12 +/- 0.007 vs Tg 96.12 873	
+/- 1.17, p=0.027; two to ten axons WT 10.59 +/- 0.28 vs Tg 3.83 +/- 1.22, p=0.03; eleven to 874	
twenty axons WT 0.28 +/- 0.28 vs Tg 0.04 +/- 0.04, not significant). n=2, 100 bundles from 875	
sciatic nerves were analyzed per animal. E, Electron micrographs of the sympathetic tract from 876	
20 month-old mice are shown. No myelinated fibers are present but multilammelar wrapping of 877	
axons and collagen fibrils are seen consistent with a role of Akt in wrapping. Scale bar 500 nm. 878	
F, The numbers of myelinated axons in transgenic dorsal (DR) and ventral (VR) roots at 5 879	
months were not statistically different in MyrAkt vs WT mice; n=2. SEM is shown in panels D 880	
and F. 881	
 882	
Figure 7. MyrAkt induces Rac1 activity in cultured Schwann cells. 883	
A, Western blot showing the controls (GDP, GTPγS and GST) as well as samples from non-884	
induced (-DOX) and doxycycline-induced (+DOX) Schwann cell pools transfected with the 885	
MyrAkt construct. The same –DOX and +DOX samples were loaded into two consecutive lines. 886	
B, Quantification of Rac1 and cdc42 levels. Values shown represent active GTPase levels 887	
divided by total GTPase levels and corrected for actin, which served as a loading control. All 888	
data were normalized to non-induced controls, which were set to 100. Induction of MyrAkt by 889	
addition of doxycycline to the culture media increased Rac1 activity significantly (193 +/- 25.31, 890	
p=0.01) but not cdc42 (96.82 +/- 27.11, p=0.91). After correction for total cdc42 and loading 891	
amounts, the level of active cdc42 in panel A is not significantly increased. SEM is shown. 892	
Rac1: n=4 independent sets of experiments, cdc42: n=3 independent sets of experiments. 893	
 894	
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Figure 8. Sciatic nerves of MyrAkt transgenic mice exhibit tomacular defects and 895	
activation of mTOR. 896	
A, Upper panels: Longitudinal electron micrographs of sciatic nerves from five month-old WT 897	
animals. Nodes are indicated by asterisk and the clefts by arrows. Lower panels: Longitudinal 898	
electron micrographs of sciatic nerves from transgenic animals reveal myelin infolding at the 899	
paranodes (left panel) and tomacula near the clefts (indicated with arrows) resulting in 900	
compression of the axon (right panel). Scale bars 5 µm. B, Example of the different myelin 901	
abnormalities observed in sciatic nerves: I, tomacula, showing compression of the axon; II, 902	
infolding and III, outfolding. Scale bars 5 µm. C, Percentages for each of the major myelin 903	
abnormalities found in cross-sections from 3 months-old transgenic sciatic nerves. n=3. D, 904	
Teased fibers from six-month-old transgenic mice show an example of an asymmetric 905	
tomacular defect with enlargement in the paranodal region of the left myelin sheath but not the 906	
right myelin sheath (asterisk marks node). E, Western blot analysis of extracts from nerves 907	
from 2 month-old WT and transgenic mice show activation of the mTOR pathway. F, 908	
Quantification of Western blots demonstrates phosphorylated S6RP is increased in Tg nerves 909	
(218.4 +/- 25.79, p=0.01) and the ratio of phosphorylated to total S6RP is also increased (167.1 910	
+/- 16.04, p=0.014); data were normalized to WT values arbitrarily set to 100. Increased 911	
phosphorylation of GSK3b and 4EBP1 were also evident but did not reach statistical 912	
significance. n=3. SEM is shown. 913	
 914	
Figure 9. Rapamycin treatment reduces myelin abormalities in CNP-MyrAkt transgenic 915	
mice. 916	
A, The phenotype of three month-old transgenic mice was largely corrected by treatment with 917	
rapamycin for eight weeks (MyrAkt+Rapa) but not by vehicle (MyrAkt+vehi); no changes were 918	
detected in control animals treated with vehicle (WT+Vehi). B, Phosphorylation of S6RP was 919	
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substantially decreased in the nerves of WT and MyrAkt mice treated with rapamycin. C, 920	
Analysis of several parameters are shown for WT mice treated with vehicle, and for transgenics 921	
(Myr) treated either with vehicle or rapamycin. These include brain weight (WT+Vehi 393 mg 922	
+/- 6.3; Myr+Vehi 438 +/- 10.2, p=0.019; Myr+Rapa 371+/- 4.75, p=0.004), the number of 923	
axons per 100 µm2 (WT+Vehi 3.4 +/- 0.2; Myr+Vehi 2.3 +/- 0.07, p=0.01; Myr+Rapa 3.6 +/- 924	
0.18, p=0.002) and the ratio of myelin abnormalities (i.e. tomacula and myelin 925	
in/outfoldings)/total axons counted (WT+Vehi 0.2% defect +/- 0.03; Myr+Vehi 3.6% +/- 0.6, 926	
p=0.003; Myr+Rapa 0.67% +/- 0.14, p=0.006). n=3. More than 3000 axons per n were 927	
examined to obtain the percentage of abnormalities. SEM is shown. D, G-ratios were measured 928	
for small myelinated fibers in the dorsal roots of wild type mice on vehicle (WT+V), transgenics 929	
on Vehicle (Myr+V) and transgenics treated with rapamycin (Myr+R). Quantification of 930	
WT+Vehi (0.62 +/- 0.006), Myr+Vehi (0.54 +/- 0.01, p<0.001) and Myr+Rapa (0.59 +/- 0.02, 931	
p=0.048) demonstrates a significant increase in the g-ratio of transgenic mice treated with 932	
rapamycin. 112 - 175 small caliber axons (0.5 to 2 µm) were measured per condition. n=4. 933	
SEM is shown. E, Rapamycin administration does not prevent the excess of membrane 934	
wrapping in the Remak bundles from 3 months old MyrAkt nerves. Schwann cells are 935	
pseudocolored in yellow and axons in the bundle in blue. Scale bar 1 µm. 936	








